Bartosz Chmielowski

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 21 papers. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763

N/A

5.4DataRank · unranked

446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Non-viral precision T cell receptor replacement for personalized cell therapy

Nature(2022)10.1038/s41586-022-05531-1

N/A

4.1DataRank · unranked

281 citations

Kyle Jacoby, Daniela A. Bota, Theresa Hunter, Zheng Pan, Eric Stawiski +49 more

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2021)10.1016/j.ccell.2020.11.015

N/A

1.9DataRank · unranked

53 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo +31 more

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

The Lancet(2024)10.1016/s0140-6736(24)01812-9

N/A

1.4DataRank · unranked

84 citations

Karla V. Ballman, Angela Hong, Scott M. Schuetze, Andrew J. Wagner, Varun Monga +23 more

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Nature(2014)10.1038/nature13954

N/A

1.3DataRank · unranked

6579 citations

Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert +28 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2007

N/A

0.965DataRank · unranked

32 citations

Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey +19 more

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3313

N/A

0.659DataRank · unranked

80 citations

Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen +12 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

Nature Communications(2025)10.1038/s41467-025-60816-z

N/A

0.281DataRank · unranked

4 citations

Nataly Naser Al Deen, Cole W. Peters, Begoña Comı́n-Anduix, Egmidio Medina, Cristina Puig-Saus +28 more

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9559

N/A

0.165DataRank · unranked

2 citations

Yue Zheng, Michael B. Atkins, Bartosz Chmielowski, Ahmad A. Tarhini, Thach‐Giao Truong +14 more

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Nature(2023)10.1038/s41586-023-05787-1

N/A

0DataRank · unranked

203 citations

Barbara Sennino, Songming Peng, Clifford L. Wang, Zheng Pan, Benjamin Yuen +51 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502

N/A

0DataRank · unranked

21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.36_suppl.356154

N/A

0DataRank · unranked

111 citations

Sandra J. Lee, Bartosz Chmielowski, Antoni Ribas, Ahmad A. Tarhini, Thach‐Giao Truong +9 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

The landscape of drug sensitivity and resistance in sarcoma

Cell stem cell(2024)10.1016/j.stem.2024.08.010

N/A

0DataRank · unranked

61 citations

Peyton Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini, Ardalan Davarifar +26 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2020)10.1016/j.ccell.2020.08.005

N/A

0DataRank · unranked

389 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo +31 more